{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:10:31Z","timestamp":1792185031284,"version":"4.4.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Patients with high-risk opioid use may require higher buprenorphine doses to maximize abstinence and retention in treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the efficacy and safety of 100-mg vs 300-mg once-monthly maintenance doses of extended-release buprenorphine among individuals with high-risk opioid use, including fentanyl.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This multicenter, randomized, double-blind clinical trial was conducted from October 26, 2021, to June 26, 2024, at 28 outpatient treatment centers in the US and Canada among treatment-seeking participants with moderate or severe opioid use disorder who injected opioids, used high doses of opioids, or used fentanyl.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n After completing buprenorphine induction and extended-release buprenorphine initiation (week 6), participants were randomized in a 1:1 ratio to receive 8 additional 100-mg or 300-mg extended-release buprenorphine maintenance injections.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was the proportion of responders for weekly opioid use, defined as participants whose percentage of visits with opioid abstinence was 80% or more over weeks 20 to 38. Post hoc analyses were performed to identify any subgroups that might benefit more from the 300-mg than 100-mg extended-release buprenorphine maintenance dose. Adverse events, including injection-site reactions, were reported. Analysis was conducted on an intent-to-treat basis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 436 participants randomized, 435 (mean [SD] age, 41.6 [10.9] years; 248 men [57.0%]) received injections and were analyzed (218 in the 100-mg arm and 217 in the 300-mg arm). There were 44 of 218 responders (20.2%) in the 100-mg arm and 50 of 216 responders (23.2%) in the 300-mg arm (Cochran-Mantel-Haenszel difference, 2.6%; 95% CI, \u22124.7% to 9.9%). In post hoc analyses, the 300-mg maintenance dose performed significantly better than the 100-mg maintenance dose among participants who used fentanyl daily (difference, 11.1%; 95% CI, 0.4%-21.6%), used fentanyl 14 times or more per week (difference, 12.2%; 95% CI, 2.4%-22.1%), or both (difference, 15.4%; 95% CI, 4.6%-26.1%). With both dosing regimens, the frequency of opioid use decreased from more than 43 instances at screening to fewer than 3 instances by week 3 (through week 38). Extended-release buprenorphine\u2013related adverse events were similar between groups, except for injection-site reactions, which were higher in the 300-mg arm (difference, 9.2%; 95% CI, 3.7%-15.2%). Both maintenance doses were well tolerated with no new safety signals.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, both extended-release buprenorphine maintenance doses were well tolerated and effective among participants with high-risk opioid use. The 300-mg maintenance dose may perform better among individuals with heavy fentanyl use. These results are particularly relevant because individuals with opioid use disorder in North America are increasingly exposed to highly potent synthetic opioids, such as fentanyl, a driver of high levels of opioid overdose deaths.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04995029<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.48043","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:00:39Z","timestamp":1765987239000},"page":"e2548043","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of Extended-Release Buprenorphine Doses for Treating High-Risk Opioid Use"],"prefix":"10.1001","volume":"8","author":[{"given":"Rajinder","family":"Shiwach","sequence":"first","affiliation":[{"name":"Adams Clinical Research, Desoto, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[{"name":"Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"Alho","sequence":"additional","affiliation":[{"name":"HUS Internal Medicine and Rehabilitation, University of Helsinki, Helsinki, Uusimaa, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Kahlert Institute for Addiction Medicine, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Strafford","sequence":"additional","affiliation":[{"name":"Research and Development, Indivior Inc, North Chesterfield, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[{"name":"Research and Development, Indivior Inc, North Chesterfield, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Dobbins","sequence":"additional","affiliation":[{"name":"Research and Development, Indivior Inc, North Chesterfield, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"zoi251293r3","journal-title":"J Addict Med"},{"issue":"3","key":"zoi251293r4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi251293r5","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/dar.13394","article-title":"Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: a case series.","volume":"41","author":"Shearer","year":"2022","journal-title":"Drug Alcohol Rev"},{"issue":"10","key":"zoi251293r6","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/add.15954","article-title":"Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine\/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.","volume":"117","author":"Socias","year":"2022","journal-title":"Addiction"},{"issue":"1","key":"zoi251293r7","article-title":"Precipitated opioid withdrawal after buprenorphine administration in patients presenting to the emergency department: a case series.","volume":"4","author":"Spadaro","year":"2023","journal-title":"J Am Coll Emerg Physicians Open"},{"issue":"4","key":"zoi251293r8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/ADM.0000000000001155","article-title":"Association of urine fentanyl concentration with severity of opioid withdrawal among patients presenting to the emergency department.","volume":"17","author":"Thakrar","year":"2023","journal-title":"J Addict Med"},{"issue":"4","key":"zoi251293r9","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl.","volume":"16","author":"Varshneya","year":"2022","journal-title":"J Addict Med"},{"issue":"6","key":"zoi251293r10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids.","volume":"17","author":"Weimer","year":"2023","journal-title":"J Addict Med"},{"issue":"10173","key":"zoi251293r13","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"zoi251293r15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/ADM.0000000000000517","article-title":"Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study.","volume":"13","author":"Ling","year":"2019","journal-title":"J Addict Med"},{"key":"zoi251293r16","article-title":"18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: integrated analysis of phase 3 studies.","volume":"154","author":"Rutrick","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"1","key":"zoi251293r17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12954-023-00906-7","article-title":"Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.","volume":"20","author":"Greenwald","year":"2023","journal-title":"Harm Reduct J"},{"issue":"9","key":"zoi251293r18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl.","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi251293r19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/00952990.2011.596974","article-title":"Participant characteristics and buprenorphine dose.","volume":"37","author":"Hillhouse","year":"2011","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"8","key":"zoi251293r20","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/ajad.12641","article-title":"Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.","volume":"26","author":"Romero-Gonzalez","year":"2017","journal-title":"Am J Addict"},{"issue":"20","key":"zoi251293r21","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"zoi251293r23","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi251293r24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1037\/a0027945","article-title":"Concurrent validity of an online version of the Timeline Followback assessment.","volume":"26","author":"Pedersen","year":"2012","journal-title":"Psychol Addict Behav"},{"issue":"6","key":"zoi251293r26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial.","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"key":"zoi251293r27","first-page":"1323","year":"1989","journal-title":"Biometrics"},{"issue":"2","key":"zoi251293r28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2024.3836","article-title":"Capturing the full range of buprenorphine treatment response.","volume":"82","author":"Bailey","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"zoi251293r30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"zoi251293r31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1052113","article-title":"Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder.","volume":"13","author":"Laffont","year":"2022","journal-title":"Front Pharmacol"},{"issue":"6","key":"zoi251293r32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.17377","article-title":"Extended-release injection vs sublingual buprenorphine for opioid use disorder with fentanyl use: a post hoc analysis of a randomized clinical trial.","volume":"7","author":"Nunes","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi251293r33","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108147","article-title":"Protracted renal clearance of fentanyl in persons with opioid use disorder.","volume":"214","author":"Huhn","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi251293r11","year":"2025"},{"key":"zoi251293r12","year":"2022"},{"key":"zoi251293r14"},{"key":"zoi251293r22","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"zoi251293r25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Measuring Alcohol Consumption","author":"Sobell","year":"1992"},{"key":"zoi251293r1","unstructured":"Ahmad? FB, Cisewski? JA, Rossen? LM, Sutton? P. Provisional drug overdose death counts. National Center for Health Statistics. 2024. Accessed July 17, 2024. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"zoi251293r2","unstructured":"Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: treatment improvement protocol 63. Substance Abuse and Mental Health Services Administration. Accessed August 16, 2024. https:\/\/store.samhsa.gov\/sites\/default\/files\/pep21-02-01-002.pdf"},{"key":"zoi251293r29","unstructured":"Ahrnsbrak R, Bose J, Hedden SL, Lipari RN, Park-Lee E. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration. 2017. Accessed May 31, 2025. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH-FFR1-2016\/NSDUH-FFR1-2016.htm?"},{"key":"zoi251293r34","unstructured":"Mandatory guidelines for federal workplace drug testing programs\u2014authorized testing panels. Substance Abuse and Mental Health Services Administration. Fed Regist. 2025;90(10). Accessed May 28, 2025. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2025-01-16\/pdf\/2025-00425.pdf?"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2842881\/shiwach_2025_oi_251293_1767730510.85245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:00:19Z","timestamp":1767974419000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2842881"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.48043","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}